Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

With drug development in China growing rapidly, Catalent has doubled down on its clinical supply capabilities in Shanghai.

Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.

Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.

AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.

Daiichi is transitioning from CV and metabolic diseases to oncology, and it says now is the right time for a new CEO to take the helm.

Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.

Eisai starts pivotal BAN2401 Alzheimer's trial; AZ helps build new life sciences hub in China; Ono secures a chance to license British I-O programs.